Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived

Hepatology

Volumn 46, Issue 6, 2007, Pages 1685-1687

  Ginès, Pere ^a   Guevara, Mónica ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; MIDODRINE; ORNIPRESSIN; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASOPRESSIN DERIVATIVE;

ALBUMIN DIALYSIS; ASCITES; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HEPATORENAL SYNDROME; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; HYPOVOLEMIA; KIDNEY CIRCULATION; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; PERIPHERAL ISCHEMIA; PERITONEAL CAVITY; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SURVIVAL TIME;

HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; VASOCONSTRICTOR AGENTS;

EID: 37749020522     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22097     Document Type: Editorial

References (25)

1. Ginès P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003;362:1819-1827.
2. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jimenez W, Arroyo V, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. HEPATOLOGY 2005;41:1282-1289.
3. Rimola A, Navasa M, Grande L, García-Valdecasas JC. Liver transplantation in patients with cirrhosis and ascites. In: Ginès P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Oxford, England: Blackwell; 2007:271-285.
4. Ginès P, Cardenas A, Arroyo V, Rodes J. Current concepts - management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
5. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. HEPATOLOGY 2006;43:385-394.
6. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007;46:935-946.
7. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956;271:1121-1125.
8. Lieberman FL, Denison EK, Reynolds TB. Relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis - overflow theory of ascites formation. Ann N Y Acad Sci 1970;170:202.
9. Epstein M. Hepatorenal syndrome. In: Epstein M, ed. The Kidney in Liver Disease. Philadelphia, PA: Hanley & Belfus; 1996:75-108.
10. Epstein M. Peritoneovenous shunt in the management of ascites and the hepatorenal-syndrome. Gastroenterology 1982;82:790-799.
11. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. HEPATOLOGY 1988;8:1151-1157.
12. Shapiro MD, Nicholls KM, Groves BM, Kluge R, Chung HM, Bichet DG, et al. Interrelationship between cardiac-output and vascular-resistance as determinants of effective arterial blood-volume in cirrhotic-patients. Kidney Int 1985;28:206-211.
13. Nicholls KM, Shapiro MD, Kluge R, Chung HM, Bichet DG, Schrier RW. Sodium-excretion in advanced cirrhosis - effect of expansion of central blood-volume and suppression of plasma-aldosterone. HEPATOLOGY 1986;6:235-238.
14. Guevara M, Ginès P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. HEPATOLOGY 1998;27:35-41.
15. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. HEPATOLOGY 1999;30:870-875.
16. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Teuber P, et al. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS) [Abstract LB6]. HEPATOLOGY 2006;44(Suppl 1):694A.
17. Martin-Llahí M, Pépin M, Guevara M, Monescillo A, Soriano G, Torre A, et al. Terlipressin and albumin versus albumin alone in patients with cirrhosis and hepatorenal syndrome. A randomized, comparative study [Abstract 82]. J Hepatol 2007;46(Suppl 1):S36.
18. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-Thoraval F, et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study. HEPATOLOGY 2002;36:374-380.
19. Alessandria C, Ottobrelli A, Debernardi-Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007;47:499-505.
20. Alessandria C, Venon W, Marzano A. Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol 2002;14:1363-1368.
21. Ortega R, Ginès P, Uriz J, Cardenas A, Calahorra B, De Las HD, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. HEPATOLOGY 2002;36(pt 1):941-948.
22. Ginès P, Uriz J, Calahorra B, García-Tsao G, Kamath PS, Del Arbol LR, et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002;123:1839-1847.
23. Krag A, Moller S, Henriksen JH, Niels-Henrik HR, Finn L. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. HEPATOLOGY 2007;46. DOI: 10.1002/hep.22038.
24. Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. HEPATOLOGY 1998;28:937-943.
25. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007;46:213-221.